2007
Structure-Activity Relationship of Substituted Pyridyl Phenyl Oxazolidinone Derivatives, Including TR-700 (DA-7157). W.B.IM, S.H.CHOI and J.K.RHEE, Dong-A Pharm., Yongin, Korea. 2007 ICAAC, Chicago, IL. (PDF 84 KB)
Single and Repeated-dose Toxicity of TR-701 (DA-7218) in Rodents. D.H. KIM, H.K. JUNG, S.H CHOI, W.B. IM and J.K. RHEE, Dong-A Pharm., Yongin, Korea. 2007 ICAAC, Chicago, IL. (PDF 140 KB)
Pharmacokinetics of TR-701 (DA-7218), a New Oxazolidinone in Mice, Rats, and Dogs. E.J. KIM, S.H. CHOI, W.B. IM, J.K. RHEE; Dong-A Pharm., Yongin-Si, Republic of Korea. 2007 ICAAC, Chicago, IL. (PDF 132 KB)
In vitro and In vivo Antibacterial Activity of TR-701 (DA-7218) against Penicillin-resistant Streptococcus pneumoniae. S. H. CHOI*, T. SON, W. B. IM and J. K. RHEE, Dong-A Pharm., Yongin, Korea. 2007 ICAAC, Chicago, IL. (PDF 128 KB)
The New Oxazolidinone, TR-700 (DA-7157): Effects of pH, Inoculum, Serum and Media on Antibacterial Activity. S. H. CHOI*, W. B. IM and J. K. RHEE; Dong-A Pharm., Yongin, Korea. 2007 ICAAC, Chicago, IL. (PDF 144 KB)
In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, Against MRSA and VRE with Defined Linezolid Resistance Mutations. K. J. SHAW1, S. POPPE 2, R. SCHAADT 2, V. BROWN-DRIVER 1, J. FINN 1, D. SHINABARGER 2, G. ZURENKO 2; 1Trius Therapeutics, San Diego, CA, 2Micromyx, Kalamazoo, MI. 2007 ICAAC, Chicago, IL. (PDF 124 KB)
The In Vitro Activity of TR-700, the Active Ingredient of the Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent. R. SCHAADT, D. SWEENEY, D. SHINABARGER, G. ZURENKO; Micromyx, Kalamazoo, MI. 2007 ICAAC, Chicago, IL. (PDF 100 KB)
TR-701 is Significantly More Potent than Linezolid in Skin and Soft Tissue Models of Infection. J. K. Rhee, T. K. Son, T. H. Lee and S. H. Choi, Dong-A Pharm, Yongin, Korea. 2007 ICAAC, Chicago, IL. (PDF 68 KB)
Selection of Optimal Antisense Clones of Bacillus anthracis for Drug Discovery Efforts V. BROWN-DRIVER, K. GC, D. REYES, M. STIDHAM, J. FINN, R. HASELBECK, M. HILGERS, K. J. SHAW; Trius Therapeutics, San Diego, CA, 2Micromyx, Kalamazoo, MI. 2007 ICAAC, Chicago, IL (PDF 140 KB)
Specific Synergistic Effect of Mur Pathway Antisense Clones of Bacillus anthracis Against β-Lactams. KEDAR GC, V. BROWN-DRIVER, D. REYES, M. STIDHAM, J. FINN, M. HILGERS, R. HASELBECK, K. J. SHAW; Trius Therapeutics, San Diego, CA, 2Micromyx, Kalamazoo, MI. 2007 ICAAC, Chicago, IL (PDF 180 KB)
Identification of Novel Inhibitors of Methionyl-tRNA Synthetase by Virtual Screening J. FINN , M. STIDHAM, M. HILGERS, K. GC.; 1Trius Therapeutics, San Diego, CA (PDF 152 KB)
Evaluation of the metS and murB Loci for Antibiotic Discovery Using Targeted Antisense RNA Expression Analysis in Bacillus anthracis
(PDF 216kb)
Full paper availble at:
http://aac.asm.org/cgi/reprint/51/5/1708
ASM Biodefense Poster (PDF 263kb)
2006
Interscience Conference on Antimicrobial Agents and Chemotherapy Poster (ICAAC) (PDF 80kb)
Gordon Research Conference Poster (PDF 7.4MB)
2005
Interscience Conference on Antimicrobial Agents and Chemotherapy Poster (ICAAC) (PDF 99kb)
Fluidigm White Paper (PDF 129kb)
